NCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
Clinical Trials
5 trialsNCT05177211 2025-12-15
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT05127174 2025-12-04
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT04955938 2024-07-31
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
University of Chicago
Phase 1 Withdrawn
NCT05524857 2024-04-23
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Columbia University
Phase 1 Terminated